Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 0.07.

  • Sangamo Therapeutics' Equity Ratio fell 7997.63% to 0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07, marking a year-over-year decrease of 7997.63%. This contributed to the annual value of 0.22 for FY2024, which is 5531.53% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Equity Ratio stood at 0.07 for Q3 2025, which was down 7997.63% from 0.2 recorded in Q2 2025.
  • Sangamo Therapeutics' Equity Ratio's 5-year high stood at 0.76 during Q1 2023, with a 5-year trough of 0.06 in Q1 2025.
  • Over the past 5 years, Sangamo Therapeutics' median Equity Ratio value was 0.52 (recorded in 2022), while the average stood at 0.44.
  • As far as peak fluctuations go, Sangamo Therapeutics' Equity Ratio soared by 4899.85% in 2023, and later plummeted by 8704.94% in 2025.
  • Over the past 5 years, Sangamo Therapeutics' Equity Ratio (Quarter) stood at 0.52 in 2021, then rose by 0.85% to 0.52 in 2022, then dropped by 4.38% to 0.5 in 2023, then tumbled by 55.32% to 0.22 in 2024, then crashed by 68.56% to 0.07 in 2025.
  • Its last three reported values are 0.07 in Q3 2025, 0.2 for Q2 2025, and 0.06 during Q1 2025.